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ABSTRACT: Drug monitoring is crucial for providing
accurate and effective care; however, current methods (e.g.,
blood draws) are inconvenient and unpleasant. We aim to
develop a non-invasive method for the detection and
monitoring of drugs via human skin. The initial development
toward this aim required information about which drugs,
taken orally, can be detected via the skin. Untargeted liquid
chromatography−mass spectrometry (LC−MS) was used as it
was unclear if drugs, known drug metabolites, or other
transformation products were detectable. In accomplishing
our aim, we analyzed samples obtained by swabbing the skin
of 15 kidney transplant recipients in five locations (forehead,
nasolabial area, axillary, backhand, and palm), bilaterally, on
two different clinical visits. Untargeted LC−MS data were processed using molecular networking via the Global Natural
Products Social Molecular Networking platform. Herein, we report the qualitative detection and location of drugs and drug
metabolites. For example, escitalopram/citalopram and diphenhydramine, taken orally, were detected in forehead, nasolabial,
and hand samples, whereas N-acetyl-sulfamethoxazole, a drug metabolite, was detected in axillary samples. In addition,
chemicals associated with environmental exposure were also detected from the skin, which provides insight into the
multifaceted chemical influences on our health. The proof-of-concept results presented support the finding that the LC−MS
and data analysis methodology is currently capable of the qualitative assessment of the presence of drugs directly via human
skin.
Human skin is a complex chemical interface between ourinternal biology and the external world. Chemicals
present on the skin originate from many sources, including
human metabolism, microbes, behaviors (such as smoking),
food, personal care products, the environment, and drugs. In
comparison with urine and blood, the chemicals on and in the
skin are poorly characterized. Information about the skin
metabolome is limited, currently, but appears to be highly
reflective of our human behaviors,1 our built environments,2,3
and the objects4 with which we interact.
Drug monitoring, for therapeutic, toxic, and adherence
purposes, is important for providing accurate and effective care.
Therapeutic drug monitoring, critical for narrow therapeutic
range drugs, strives to measure the concentration of a drug (or
metabolite) in blood to determine if the drug is within a
therapeutic window (i.e., sufficient to be effective but not too
much as to cause side effects). Routine blood draws are
inconvenient and unpleasant. Adherence testing, intended to
objectively determine if prescriptions are being followed, is
similarly important in providing optimal care but suffers from
being inconvenient (e.g., urine or blood collection).
Drugs and drug metabolites are routinely measured in blood,
urine, saliva, and other blood fluids and tissues using mass
spectrometry. Mass spectrometry (MS), often coupled to
chemical separation methods prior to analysis [e.g., gas
chromatography (GC) or liquid chromatography (LC)], has
been used to analyze the chemical composition of skin.1,4−10
MS detects the mass-to-charge ratio (m/z) of ions, charged
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versions of neutral molecules, at minute levels (often in the low
parts per billion range) and provides structural information
using multiple stages of MS (e.g., MS2). Structural information
is provided via interpretable fragmentation patterns when
excess internal energy is supplied to ions, for example, via
collision with gas molecules, i.e., collision-induced dissociation
(CID).
There is a prior basis for the detection of drugs via the skin.
There have been numerous studies that measured the amount
of drug, applied topically, to the skin as well as the depth of
drug penetration.11−13 Prior studies were commonly per-
formed in vitro, or sample collection was performed using tape
stripping,7 skin scraping,9 or punch biopsy.14 Non-invasive
sampling of the skin with swabs is far less invasive, but the
following limitations exist currently: sampling is qualitative and
user-dependent and provides molecular information only from
the outermost layers of the epidermis. With regard to the
detection of drugs taken orally, there are only a few studies that
suggest that detection is possible from the skin of
individuals,4,15 but the information present in those studies
was not sufficient to understand, in detail, which drugs can be
detected via the skin, at which body locations they are
detectable, and by which mechanism(s) drugs arrive on or in
the skin.
Untargeted MS in its purest form intends to detect all
chemicals present in a given sample without knowledge of the
composition a priori; the metabolome is a subset of those
chemicals. In this instance, untargeted MS serves to broadly
screen for drugs (and potential metabolites) from the skin,
particularly drugs taken orally, without any prior knowledge if
certain chemicals are present on the skin. One challenge in
performing untargeted MS is the analysis of a large amount of
data generated. Our solution is to use the Global Natural
Products Social Molecular Networking (GNPS) platform.16
Molecular networking connects chemicals of similar structure
based on MS2 data (specifically product ion scans) as similar
molecular structures often produce similar MS2 fragmentation
patterns. The first step is to generate consensus MS2 spectra
(represented as nodes in the molecular network) by
consolidating nearly identical MS2 spectra. The consensus
MS2 spectra are compared and connected via edges and given a
cosine score based on the similarity of MS2 fragmentation.
Grouping of connected consensus spectra (i.e., molecular
families) indicates similar fragmentation patterns and a similar
molecular structure and reflects chemicals grouped by chemical
class. Chemical annotation is performed in GNPS by
comparing consensus MS2 spectra with reference MS2
fragmentation patterns (and supported by accurate measure-
ment of m/z). GNPS annotations via spectral reference
comparison are considered level 2 (putative annotation based
on spectral library similarity) or 3 (putatively characterized
compound class based on spectral similarity to known
compounds of a chemical class) by the 2007 metabolomics
standard initiative.17
Herein, we report the untargeted MS analysis of skin swabs
from the face, hands, and axilla (sampled bilaterally and
longitudinally at two clinical visits) of 15 kidney transplant
recipients. Specific to our aim in developing a non-invasive
method for the detection and monitoring of drugs from the
skin, we report (1) the drugs detected by untargeted MS and
confirmed using MS2 spectra, (2) the locations at which drugs
(and metabolites) were detected, and (3) concurrent detection
of chemicals associated with environmental exposure and
health. This work describes the initial steps in developing the
technology necessary for non-invasive drug monitoring via the
skin.
■ EXPERIMENTAL SECTION
Study Design. Figure 1 illustrates the sample collection
and experimental workflow used in this study. Skin samples
were collected following an IRB-approved study (University of
California, San Diego, IRB 161371) from kidney transplant
patients; data from 15 subjects were used in this work. Ten
locations on the body (bilateral collection of the forehead,
nasolabial area, axillary, backhand, and palm) were sampled per
subject at two different times, once during a routine clinic visit
(clinic) and once at a subsequent clinical visit (lab). The
following numbers of samples per body location were used: n =
59 for forehead, n = 59 for nasolabial area, n = 60 for axillary, n
= 60 for backhand, and n = 60 for palm. Table S1 displays the
number of samples collected and included in this work.
Metadata pertaining to each sample were collected in
accordance with IRB and HIPAA authorization and
deidentified and are available in the Supporting Information.
The metadata included detailed drug information that is
highlighted in the Supporting Information.
Samples. Cotton swabs (Puritan 837 without binders)
were soaked in an ethanol/water mixture (1:1) prior to
sampling three times to minimize the chemical background
observed from the swabs. Swabs moistened with an ethanol−-
water mixture (1:1) were used to sample the subject’s skin.
Samples were collected by rubbing the skin in a circular pattern
for ∼10 s with moderate, painless, pressure. Swab tips were cut
into 96 deep-well plates, sealed, and stored at −80 °C prior to
extraction.
Sample Extraction. Skin swabs in 96 deep-well plates were
extracted using 1.2 mL of 100% methanol pipetted using a
multichannel pipet. The 96 deep-well plates were capped and
sonicated for 300 s. Subsequently, the cap was removed, and
Figure 1. Illustration depicting the sampling of the skin of 15 subjects
in 10 locations using a premoistened cotton swab and the subsequent
sample handling, data acquisition, and data processing in GNPS.
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the swabs were removed using a tweezer (rinsing with
nanopure water between samples). Aliquots (300 μL) were
transferred to 96-well plates and dried via centrifugal
evaporation. Samples were resuspended in an acetonitrile−-
water mixture (1:4) prior to LC−MS analysis. Axillary samples
were diluted 10-fold to avoid detector saturation.
Data Acquisition. The skin samples were analyzed using
an ultra-high-performance liquid chromatograph (UltiMate
3000, Thermo) coupled to a quadrupole time-of-flight (ToF)
mass spectrometer (maXis Impact, Bruker). Chromatographic
separation was carried out on a Kinetex C18 1.7 μm, 100 Å, 2.1
mm (internal diameter) × 50 mm (length) column
(Phenomenex) maintained at 40 °C during separation; 10.0
μL of extract was injected per sample, except for axillary
samples, which were injected in 1.0 μL amounts to avoid
saturation of the detector. Mobile phase A consisted of water
with 0.1% formic acid (v/v), and mobile phase B consisted of
acetonitrile with 0.1% formic acid (v/v). Gradient elution was
performed as follows: 5% B from 0.0 to 0.5 min, 100% B from
0.5 to 8.0 min, 100% B from 8.0 to 9.0 min, 5% B from 9.0 to
9.1 min, and 5% B from 9.1 to 12.5 min. MS data were
collected using data-dependent acquisition. An MS1 scan from
m/z 50 to 1500 at 3 Hz was followed by MS2 scans.
Fragmentation was produced by stepped collision-induced
dissociation (CID) of the five most abundant ions in the prior
MS1 scan. Electrospray ionization, positive mode, was used to
convert solution-phase molecules into gas-phase ions for MS
analysis using the following source parameters: drying gas, 9.0
L min−1; dry gas heater, 200 °C; capillary voltage, 4.5 kV; end
plate offset, −0.5 kV; and nebulizer, 2.0 bar. Hexakis(2,2-
difluoroethoxy)phosphazene, lock mass standard, was sub-
limed in the ionization source; the lock mass standard was
added such that a signal of ∼1 × 105 was observed.
Data and Code Availability. All MS data (.d and.mzXML
files) are publically available via GNPS/MassIVE (massive.ucs-
d.edu), a public MS data repository, under accession number
MSV000081548. All data, files, and Jupyter notebooks (R)
used to process data and generate plots are freely available at
github.com/alan-jarmusch/UntargetedMS-Drugs-Skin.
Data Processing and Data Analysis. The qToF files (.d)
were exported using DataAnalysis (Bruker) as .mzXML files
after lock mass correction. Feature finding was performed on
MS1 data in MZmine2,18 and parameters can be found in the
Supporting Information, yielding a data matrix of MS1 features
(i.e., m/z and retention time) and associated peak area. MS2
data were analyzed using GNPS.16 Figures were generated with
Jupyter Notebooks (R), Cytoscape,19 Bruker DataAnalysis,
‘ili,20 and formatted in Adobe Illustrator. Additional
description of the data analysis methods is present in the
Supporting Information.
Molecular Networking and Annotation in GNPS. Molec-
ular networking was performed with networking parameters
that reflect a false-discovery rate (FDR) of annotation of ∼1%;
FDR estimation was performed using the Passatutto-GNPS
Library Search tool (Figure S1).21 The data were filtered by
removing all MS2 peaks m/z ± 17 of the precursor ion. MS2
spectra were window filtered by choosing only the top six
peaks in the m/z ± 50 window throughout the spectrum. The
data were then clustered with MS-Cluster with a precursor and
product ion mass tolerance of m/z 0.02 to create consensus
MS2 spectra. Then, to remove noisy data and data that were
not reproducible, consensus spectra that contained fewer than
two spectra were discarded. A network was then created where
edges were filtered to have a cosine score above 0.75 and more
than five matched peaks. In addition, edges between two nodes
were kept in the network only if each of the nodes appeared in
each other’s respective top 10 most similar nodes. The
consensus MS2 spectra in the network were then searched
against spectral libraries in GNPS. The library spectra were
filtered in the same manner as the input data. All matches kept
between network spectra and library spectra were required to
have a score above 0.75 and at least five matched peaks;
141275 MS2 spectra were submitted to GNPS, of which
108118 were included in the molecular network. Those
108118 spectra were consolidated into 9644 consensus MS2
spectra displayed as nodes in the full molecular network
(Figure S2A). Consensus MS2 spectra can be used as a proxy
measure of the number of chemicals detected using untargeted
MS; however, overestimation is likely as the same chemical can
form different ion species in the instrument (e.g., [M + H]+
and [M + Na]+) as well as isotopologues (e.g., [C6H6O6 +
Na]+ and [13C1
12C5H6O6 + Na]
+), which results in additional
consensus MS2 spectra. Then, 2.07% of consensus MS2 spectra
(200 of 9644) (Figure S2B) were annotated via GNPS, which
corresponded to 77 unique chemicals (including the previously
mentioned drugs). The rate of annotation is not uncommon in
untargeted MS experiments of sample types less frequently
investigated, in spite of using GNPS, which aggregates nearly
all publicly accessible reference spectra. The molecular
networking job is public (https://gnps.ucsd.edu/Pro-
teoSAFe/status.jsp?task=bbee697a63b1400ea585410-
fafc95723).
Source Tracking of GNPS-Annotated Chemicals and
Differential Association Testing. The spectral library search
function in GNPS, an integrated component of molecular
networking, was used to annotate consensus MS2 data.
Annotated chemicals were tabulated as detected (i.e., 1) or
not detected (i.e., 0) in each sample and output as a matrix,
dubbed the chemical occurrence matrix. In parallel, the GNPS
annotations were compiled into a manually curated source
information table provided as Supporting Information.
Annotated molecules were traced to a putative origin, i.e.,
source tracking, using heuristic or empirical information from
published literature and chemical databases (e.g., PubChem).
The chemical occurrence matrix and source information table
were subsequently combined and processed in R. Annotations
to the same chemical in the chemical occurrence matrix were
collapsed into a single entry prior to data analysis. Multiple
annotations for the same chemical can occur, often based on
slight differences in the MS2 product ion spectra that match
different library spectra for the same chemical. The chemical
occurrence matrix was output from R as a .csv file (samples in
rows by variables in columns with metadata prepended to the
beginning of the data matrix). In addition, a new matrix
containing the source-tracking information, termed the source-
tracking matrix (annotations in rows by samples in columns),
was output from R as a .csv file.
Differential association testing of the chemical annotations
(provided by GNPS in the chemical occurrence matrix) and
categorical metadata groups was performed using a Fisher’s
exact test. P values were corrected for multiple-hypothesis
testing using the FDR method.22
Molecular Cartography of MS2 Data. The MS2 source-
tracking matrix (output from GNPS) was merged with
metadata on a sample-by-sample basis in a Jupyter notebook
in R. Additional metadata required for plotting data in ‘ili, a
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software for three-dimensional (3D) molecular cartography,20
were added to the data−metadata table on the basis of the
sample location (i.e., x, y, z coordinates and radii) on a 3D
androgynous model of a human (.stl) downloaded from
http://nickzucc.blogspot.com/ (free download without copy-
right). The following parameters were used for orientation and
visualization of the model: −112.62, x-axis rotation; 22.1, y-axis
rotation; −135.81, z-axis rotation; 2.5, light; #575757, color;
#ffffff, background; 1.0, opacity; 0.05, border opacity; and 1.0,
size factor.
■ RESULTS AND DISCUSSION
Detection of Drugs. Kidney transplant recipients are
closely monitored, and multiple medications are frequently
prescribed. In our cohort of 15 subjects, there were 75
prescribed medications, of which 12 were unlikely to be
detected, viz., the elemental composition of K-Phos is not
detected using our methods, via MS (rationale is given in
Table S2). Fifty-eight of the 63 medications that can be
detected had at least one reference MS2 spectrum in the GNPS
libraries that were used for annotation. GNPS was utilized to
analyze the untargeted MS data, specifically MS2 product ion
scan, as the drugs and metabolites that could be detected via
the skin were unknown. In addition, annotation based on
comparisons between observed MS2 fragmentation patterns
and MS2 reference spectra is more likely to be correct than
relying on accurate mass measurement alone, particularly when
chemical standards, e.g., drug metabolites, are not available or
prohibitively expensive.
Figure 2. Illustrative 3D molecular cartography images depicting the locations at which drugs were detected (red) or not detected (blue) based on
MS2 spectral library matching in GNPS. Timolol in subject SG5350 during (A) clinical visit 1 and (B) clinical visit 2. Escitalopram/citalopram in
subject US5662 during (C) clinical visit 1 and (D) clinical visit 2. Diphenhydramine in subject US5662 during (E) clinical visit 1 and (F) clinical
visit 2. N-Acetyl-sulfamethoxazole in subject GI1546 during (G) clinical visit 1 and (H) clinical visit 2.
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Eight prescribed drugs (escitalopram/citalopram, trimetho-
prim, mycophenolic acid, mycophenolate mofetil, diphenhydr-
amine, dioctyl sulfosuccinate, timolol, and sulfamethoxazole)
and one drug metabolite (N-acetyl-sulfamethoxazole) were
annotated via GNPS in at least one sample. The annotations
provided by GNPS spectral matching were supported by
assessing the mass error between the mass of the precursor ion
and the theoretical monoisotopic mass (<5 ppm error). The
further rationale for annotation of the drugs is discussed in the
Supporting Information. Two additional drugs were detected,
proguanil and dextromethorphan. Proguanil shares similar
fragments with chlorhexidine (detected in samples), and it is
believed to be a false positive or an in-source fragment of
chlorhexidine as there was no record of antimalarial drugs. In
addition, chlorhexidine is used in personal care products that
are topically applied, such as hand soap, as an antibacterial
agent, making this interpretation more plausible. Dextro-
methorphan was detected from only two swab samples from
the hands of one subject. Although this was not on the
patient’s drug list, it is an over-the-counter drug that is widely
available and exemplifies the advantage of an untargeted
approach in combating the often poor reliability of self-
reported drug use.
Molecular Cartography of GNPS-Annotated Drugs
Indicates Drug-Specific Distributions. We used molecular
cartography to visualize the spatiochemical (and temporal)
relationship of the detected drugs (Figure 2). Chemical
annotations from GNPS (MS2 data), either detected or not
detected, from all body locations are listed in Table 1. A
majority of annotated drugs were prescribed to the subject
from which they were detected, providing a necessary positive
control (exemplified by the following examples), supported by
differential association testing via Fisher’s exact test. Drugs
were detected in different body locations that could reflect
different mechanisms for their presence on the skin. Differ-
ential association testing results are listed in the Supporting
Information. Information about the drugs prescribed and
detected is available in the Supporting Information.
Timolol was detected on the face and hands of subject
SG5350 during the first clinical visit (Figure 2A) but was not
detected during the second clinical visit (Figure 2B), which
could reflect the timing of application; however, the time of
use prior to sampling was not available. Subject SG5350 was
prescribed Combigan (brimonidine/timolol), an ophthalmic
medication, used to treat glaucoma and ocular hypertension. It
is postulated that the presence on the face and hands occurs as
a result of application to the eyes and transference to and from
the hands to the surrounding forehead and nasolabial area.
In the case of drugs taken orally, we believe that the
detection of drugs on the hands alone is more likely to result
from transference (e.g., handling of pills) whereas detection on
the face or axilla (and combinations of different body
locations) is more likely to reflect drug elimination or
transport to the skin. For example, escitalopram, a stereo-
isomer of citalopram (indistinguishable using our methods),
was detected in the face and hand samples of subject US5662,
the only subject prescribed citalopram (p = 2.47 × 10−14),
during both clinical visits (Figure 2C,D). Citalopram,
prescribed orally to this subject, is rapidly absorbed into
systemic blood circulation and is lipophilic with high
bioavailability. Citalopram is excreted in urine (12−23%)
and feces (∼10%) unchanged.23 It is possible that
escitalopram/citalopram is present on the skin as a result of
diffusion (active or passive), sebaceous excretion, but it is also
possible that escitalopram/citalopram is sequestered in dermal
cells that eventually become part of the epidermis. Regardless
of the mechanism, which cannot be conclusively determined in
this study, the detection of escitalopram/citalopram on the
skin supports the findings of our previous study4 in which
citalopram was detected from the hand of a subject who self-
reported consuming the drug.
Diphenhydramine, an antihistamine, was detected only in
subject US5662, which matches the subjects’ drug record (p =
2.10 × 10−14). Diphenhydramine was detected on the hands
and face of the subject during both clinical visits (Figure 2E,F).
Diphenhydamine is reported to be widely distributed in the
body, metabolized extensively, and eliminated in urine.24
Diphenhydramine and escitalopram/citalopram have similar
theoretical logP values calculated in ChemDraw Professional
(3.53 and 3.86, respectively), which could suggest they follow a
similar mechanism.
While escitalopram/citalopram and diphenhydramine were
prescribed and detected in only one subject, sulfamethoxazole
was prescribed (in combination with trimethoprim, i.e.,
Bactrim SS) to all of the kidney transplant recipients per
University of California, San Diego, protocol as prophylaxis for
Pneumocystis jiroveci pneumonia. Sulfamethoxazole was anno-
tated (based on MS2) the following number of times per body
location: zero, axilla; two, face; and seven, hands. This
observation most likely results from transference during
handling of the oral formulation; however, it is also possible
that sulfamethoxazole is excreted onto or into the skin as it is
known to be distributed in tissues and fluids in the body.25 N-
Acetyl-sulfamethoxazole, the major Phase II hepatic metabolite
of sulfamethoxazole, was detected in one hand sample and
eight axilla samples (illustrated in subject GI1546 in panels G
and H of Figure 2). The observation of N-acetyl-sulfamethox-
azole in the axilla compared to hands and face was statistically
significant by differential association testing (p = 2.29 × 10−4).
N-Acetyl-sulfamethoxazole was the only drug metabolite
detected in the study through library matching (likely limited
by the poor representation of drug metabolites in the MS2
spectral libraries). A majority of sulfamethoxazole is converted
into N-acetyl-sulfamethoxazole and excreted by the kidneys.26
While we did detect N-acetyl-sulfamethoxazole, it was not
detected in all individuals prescribed sulfamethoxazole. One
rationale for these false negatives is that an MS2 spectrum was
not acquired due to a lack of signal intensity after dilution of
axilla samples. It was necessary to dilute axilla samples prior to
Table 1. Numbers of Samples in Which a Drug Was
Detected
annotated drug axillary face hands
escitalopram/citalopram 0 5 7
dextromethorphan 0 0 2
trimethoprim 0 13 17
mycophenolic acid 0 0 2
N-acetyl-sulfamethoxazole 8 0 1
proguanil 2 8 22
mycophenolate mofetil 0 1 3
diphenhydramine 0 10 11
dioctyl sulfosuccinate 0 3 0
timolol 0 5 2
sulfamethoxazole 0 2 7
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analysis to avoid saturation of the detector caused by
polypropylene glycol, present in some subject samples, which
is believed to correspond to the use of personal care products
(e.g., deodorants and antiperspirants).
The detection of N-acetyl-sulfamethoxazole in the axilla, a
location of sweat glands (eccrine and apocrine), and known
excretion of sulfamethoxazole in urine (theoretical logP of
0.57, ChemDraw Professional) suggest that N-acetyl-sulfame-
thoxazole might be secreted onto the skin via sweat. The
detection of N-acetyl-sulfamethoxazole in locations different
from those of sulfamethoxazole offers a strong contrast
between the parent drug and metabolite. More generally, the
observed differences might suggest that polar metabolites of
drugs are more likely to be found in the axilla (and other
locations of sweat glands) given that the major hepatic drug
processes are oxidative and tend to yield more polar
metabolites for renal excretion (as opposed to more nonpolar
metabolites being excreted via the bile).
Concurrent Detection of Chemicals Important to Our
Health. In addition to the detection of drugs, the untargeted
MS approach provided information about other chemicals
detected on the skin. Source-tracking information, i.e., the
putative source of chemicals based on heuristic or empirical
evidence, indicated a large number of chemicals categorized as
environmental. Environmental exposure has a large impact on
health. This information, provided at no additional cost via
concurrent analysis with GNPS, could improve care partic-
ularly when used in conjunction with drug information.
Source-tracking information for annotated chemicals was
categorized by body location (Figure S3 and Table S3). The
proportion of each source category was similar between the
skin of the face and hand but slightly different in the axilla
samples with greater portions of annotations from environ-
mental and multiple sources. The most represented source in
each body location was the environmental category (e.g.,
ultraviolet protectants, phthalates, organophosphates, and
biocides), which is notable yet not surprising as the skin is
an environmental interface and humans exhibit a large number
of behaviors that likely introduce chemicals (e.g., washing with
soap and application of cosmetics and deodorants).
Fisher’s exact test was used to test the differential association
of annotated chemicals between the different body locations
(as well as other metadata categories, e.g., gender). Dibutyl
phthalate and dioctyl phthalate were differentially associated,
statistically significantly, across different body locations (Figure
S4). Dibutyl phthalate was detected more often in the axillary
samples (p = 2.58 × 10−4), whereas dioctyl phthalate was
detected more often on the face and hands of subjects (p =
8.24 × 10−16). Diethyl phthalate was also detected but lacked
statistically significant differences between sample locations (p
= 0.271). Phthalates are common chemicals in our environ-
ment and are common in cleaning products, deodorants, and
makeup,27 and detectable levels have been reported in human
blood28 and urine;29 however, there is little information about
the detection of phthalates via the skin.30 Phthalates were not
detected in all samples and are not believed to originate from
sampling materials or analysis equipment as they are not
present in the blanks. The observed differences in the locations
of phthalates are hypothesized to reflect the application of
different personal care products such as deodorant and makeup
used on the axilla and face, respectively.
Triphenyl phosphate (a flame retardant and plasticizer) was
detected on the hands more often than on the face and axilla
(p = 1.83 × 10−4) (Figure S4) and might reflect a route of
exposure, transference from objects to the hands and potential
ingestion, which is supported by a previous study30 (Figure
S4). Benzalkonium chloride was observed on nearly 50% of all
hand samples and detected more often on hands than on other
body locations tested (p = 4.05 × 10−12). Similar to triphenyl
phosphate, we hypothesize that our observations reflect
transference from surfaces cleaned with quaternary ammonium
biocides to the hands of subjects or application of personal care
products.
■ CONCLUSIONS
The initial research toward developing a non-invasive MS
method of monitoring drugs using the skin is presented. The
exploratory goal in determining if drugs can be detected on the
skin was accomplished. In summary, only a few of the
prescribed drugs could be detected in the study. The two
parent drugs that were clearly taken orally (escitalopram/
citalopram and diphenhydramine) were observed in multiple
skin locations on multiple days. We have concluded that the
presence of these drugs most likely occurred via a systemic
process; however, transference remains a possibility in lieu of a
definitive mechanism. These drugs are lipophilic, and while
they are not known to be present in or on the skin, there is
prior knowledge that they are highly bioavailable and
distributed in the body. We also detected timolol, a topically
applied drug, supporting the idea that topical drugs can be
detected using our methods and supporting prior MS studies
of topical drugs.11−13 Finally, N-acetyl-sulfamethoxazole, an
antibiotic metabolite, was detected in the axilla samples from
subjects taking sulfamethoxazole. The detection of the hepatic
metabolite confirms that sulfamethoxazole (taken orally) is
simply not present on the skin via transference but
uncharacterized pharmacokinetics to the skin may exist. We
hypothesize the following potential mechanisms for the
presence of drugs on the skin: passive diffusion or active
transport from systemic blood circulation into the skin
epidermis, secretion of molecules via sebaceous or sweat
glands onto the epidermis, or sequestration in dermal cells that
eventually become part of the epidermis. Regardless of the
mechanism, the detection of drugs on the skin of subjects that
have been prescribed drugs has not been previously reported.
We developed the ability to link GNPS annotations with
putative source information via source tracking, which
indicated a majority of annotated molecules on the skin
originate from the environment as well as the multiple-source
category (e.g., amino acids and lipids). Differential association
testing indicated that specific molecules were present in
different body locations with statistical significance, such as the
presence of dibutyl phthalate in axilla samples or benzalkonium
chloride in hand samples. Untargeted MS analysis of skin and
data analysis via GNPS can provide insight into chemicals
beyond drugs, for no additional effort, which might impact
health, such as environmental chemicals present on the skin via
direct application of personal care products, transference from
cleaning products, etc.
On the basis of the results, qualitative drug monitoring
(present or absent) is possible with the current method while
the sensitivity and specificity could be improved by selecting
which drugs intend to be monitored a priori and modifying the
LC−MS method to more accurately and precisely acquire data
for those drugs. Improvements in sensitivity may allow
additional drugs, including those prescribed in this study that
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were not detected, to be observed. In addition, the five
bilaterally sampled locations evaluated in this study may have
limited the number of drugs detected in this study. We cannot
make a strong recommendation for sampling specific body
locations for specific drugs, but we do believe that certain
locations will be better than others for specific drugs. In
addition, axilla and face samples are less likely to have
contributions from transference compared to hand samples.
The next stage of development is improving the ability to
sample quantitatively and produce quantitative drug monitor-
ing results, critical for some drugs. We envision the
development of an accurate and precise sampling method
that samples a fixed area of skin using a controlled amount of
pressure and internal standards to correct for potential matrix
effects. One challenge that exists is to establish drug levels in
skin for which there is very little information available in the
literature. Therefore, we plan to compare blood, urine, fecal,
and skin drug levels in follow-up experiments to establish drug
levels. While there are a number of crucial development steps
that remain, the potential to reduce the inconvenience and
morbidity of therapeutic drug monitoring by supplanting blood
draws, to improve the methodology and cost of drug
adherence testing, and to improve our understanding of drug
pharmacokinetics is substantial.
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